{
    "paper_id": "79eb68edf8d4967eabc498eadd818f53ea7d52f8",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "suggest that \"the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered\".",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "We wish to clarify that different RAAS inhibitors have different effects on ACE2 levels. By acting at different levels of the system, RAAS inhibitors result in heterogeneous effects on the peptides and enzymes involved. Whereas angiotensin-receptor blockers and mineralocorticoid-receptor blockers have been shown to increase the levels of ACE2 expression and activity in various experimental and clinical models 5,6 , administration of ACE inhibitors increased cardiac Ace2 mRNA levels but had no effect on ACE2 activity in experimental models 7, 8 . In addition, in an animal model of diabetic nephropathy, the chronic administration of aliskiren (a direct inhibitor of renin) was associated with a reduction in ACE2 expression 9 . For these reasons, we believe that chronic treatment with ACE inhibitors has no reason to influence the course of SARS-CoV-2 infection. By contrast, the use of angiotensin-receptor blockers or mineralocorticoid-receptor blockers might warrant caution and further analysis in the context of SARS-CoV-2 infection. The reduced expression of ACE2 with aliskiren treatment could be an interesting option in",
            "cite_spans": [
                {
                    "start": 545,
                    "end": 547,
                    "text": "7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 548,
                    "end": 549,
                    "text": "8",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 730,
                    "end": 731,
                    "text": "9",
                    "ref_id": "BIBREF8"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Jean-Jacques Mourad and Bernard I. Levy C o r r e s p o n d e n C e Nature reviews | Cardiology",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Interaction between RAAS inhibitors and ACE2 in the context of COVID-19"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "COVID-19 and the cardiovascular system",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "Y"
                    ],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "T"
                    ],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "Y"
                    ],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat. Rev. Cardiol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41569-020-0360-5"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Role of the ACE2/angiotensin 1-7 axis of the reninangiotensin system in heart failure",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "B"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Grant",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "Y"
                    ],
                    "last": "Oudit",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Circ. Res",
            "volume": "118",
            "issn": "",
            "pages": "1313--1326",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Hypertension: renin-angiotensin-aldosterone system alterations",
            "authors": [
                {
                    "first": "Te",
                    "middle": [],
                    "last": "Riet",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Van Esch",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Roks",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Van Den Meiracker",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "Danser",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Circ. Res",
            "volume": "116",
            "issn": "",
            "pages": "960--975",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hoffmann",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.cell.2020.02.052"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Keidar",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Circ. Res",
            "volume": "97",
            "issn": "",
            "pages": "946--953",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Regul. Pept",
            "volume": "166",
            "issn": "",
            "pages": "90--97",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Ferrario",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Circulation",
            "volume": "111",
            "issn": "",
            "pages": "2605--2610",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "A human homolog of angiotensinconverting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Tipnis",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J. Biol. Chem",
            "volume": "275",
            "issn": "",
            "pages": "33238--33243",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Aliskiren inhibits angiotensin II/ angiotensin 1-7 (Ang II/Ang1-7) signal pathway in rats with diabetic nephropathy",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Ding",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": [
        {
            "text": "J.-J.M. has received fees for consultancy from Mylan, Pfizer and Servier. B.I.L. has received grants and personal fees from Bayer, Roche and Servier.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Competing interests"
        }
    ]
}